Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
Authors
Keywords
-
Journal
Infectious Diseases and Therapy
Volume 12, Issue 3, Pages 777-806
Publisher
Springer Science and Business Media LLC
Online
2023-02-27
DOI
10.1007/s40121-023-00773-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cefiderocol for the Treatment of Infections Due To Metallo-Beta-Lactamase-Producing Pathogens in the CREDIBLE-CR And APEKS-NP Phase 3 Randomized Studies
- (2022) Jean-Francois Timsit et al. CLINICAL INFECTIOUS DISEASES
- Cefiderocol for the treatment of metallo-beta-lactamases producing Gram negative bacilli: lights and shadows from the literature
- (2022) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants
- (2022) Laurent Poirel et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
- (2022) Christopher JL Murray et al. LANCET
- Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
- (2022) Patrice Nordmann et al. Microbial Drug Resistance
- Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies
- (2022) David L. Paterson et al. Infectious Diseases and Therapy
- Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
- (2022) Pranita D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales
- (2022) Rémy A. Bonnin et al. CLINICAL MICROBIOLOGY AND INFECTION
- Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
- (2022) Shio-Shin Jean et al. Frontiers in Cellular and Infection Microbiology
- An Analysis of Risk Factors for Carbapenem-resistant Enterobacteriaceae Infection
- (2022) Yan GAO et al. Journal of Global Antimicrobial Resistance
- In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
- (2022) Dee Shortridge et al. Microbiology Spectrum
- Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network
- (2022) Qi Wang et al. Microbiology Spectrum
- Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
- (2022) Peng Lan et al. Microbiology Spectrum
- Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
- (2022) Stamatis Karakonstantis et al. Antibiotics-Basel
- NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol
- (2022) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates
- (2022) Pranita D. Tamma et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials
- (2022) Christopher Longshaw et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022
- (2022) Marco Coppi et al. Eurosurveillance
- In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
- (2022) Saoussen Oueslati et al. Antibiotics-Basel
- Bloodstream Infection Due to a VIM-Metallo-β-Lactamase-Producing Klebsiella pneumoniae Treated with Cefiderocol in a Preterm Newborn
- (2022) Caterina Monari et al. Infectious Diseases and Therapy
- Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales
- (2021) Rémy A. Bonnin et al. Frontiers in Medicine
- Risk factors for transmission of carbapenem-resistant Enterobacterales to healthcare personnel gloves and gowns in the USA
- (2021) L.M. O'Hara et al. JOURNAL OF HOSPITAL INFECTION
- Predominance of Non-carbapenemase Producing Carbapenem-Resistant Enterobacterales in South Texas
- (2021) Cody A. Black et al. Frontiers in Microbiology
- Carbapenem-resistant Enterobacteriaceae among kidney transplant recipients – insights on the risk of acquisition and CRE infection
- (2021) Maristela P. Freire et al. Infectious Diseases
- Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
- (2021) Alexandre Bleibtreu et al. Microorganisms
- Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-nonsusceptible Enterobacterales collected as part of a Global Surveillance Program, 2012-2017
- (2021) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- EPIDEMIOLOGY AND TRANSMISSION OF CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE IN A HEALTHCARE NETWORK OF AN ACUTE HOSPITAL AND ITS AFFILIATED INTERMEDIATE- AND LONG-TERM CARE FACILITIES IN SINGAPORE
- (2021) Aung-Hein Aung et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular epidemiology, natural history and long-term outcomes of multi-drug resistant Enterobacterales colonization and infections among solid organ transplant recipients
- (2021) M Hong Nguyen et al. CLINICAL INFECTIOUS DISEASES
- Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect
- (2021) Claire Amaris Hobson et al. CLINICAL MICROBIOLOGY AND INFECTION
- Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae producing KPC-31, a D179Y variant of KPC-3
- (2021) Giusy Tiseo et al. Open Forum Infectious Diseases
- Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates
- (2021) Travis K Price et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity
- (2021) Diógenes Rodrigues et al. BRAZILIAN JOURNAL OF MICROBIOLOGY
- Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA
- (2021) Sabrina Klein et al. CLINICAL INFECTIOUS DISEASES
- In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
- (2021) Gabriele Bianco et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of IVACs caused by Enterobacterales in critically ill adult patients
- (2021) Milo Gatti et al. Expert Review of Anti-Infective Therapy
- No in vitro activity of cefiderocol against OXA-427-producing Enterobacterales
- (2021) Ann-Sophie Jacob et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia
- (2021) Takayuki Katsube et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pan-drug resistant Providencia rettgeri contributing to a fatal case of COVID-19
- (2021) Patrick Mc Gann et al. JOURNAL OF MEDICAL MICROBIOLOGY
- β-lactam resistance associated with β-lactamase production and porin alteration in clinical isolates of E. coli and K. pneumoniae
- (2021) Sara M. Khalifa et al. PLoS One
- An Evidence-Based Multidisciplinary Approach Focused at Creating Algorithms for Targeted Therapy of BSIs, cUTIs, and cIAIs Caused by Enterobacterales in Critically Ill Adult Patients
- (2021) Milo Gatti et al. Infection and Drug Resistance
- Risk factors for isolation of carbapenem-resistant Enterobacterales from normally sterile sites and urine
- (2021) Mary Elizabeth Sexton et al. AMERICAN JOURNAL OF INFECTION CONTROL
- New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
- (2021) Dennis Nurjadi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
- (2021) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression
- (2021) Patricia J Simner et al. CLINICAL INFECTIOUS DISEASES
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
- (2021) Mical Paul et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy
- (2021) Eric Wenzler et al. CLINICAL PHARMACOKINETICS
- Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia
- (2021) Michael R. Hovan et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies
- (2021) Thomas P. Lodise et al. Expert Review of Anti-Infective Therapy
- The surveillance of colistin resistance and mobilized colistin resistance genes in multidrug-resistant Enterobacteriaceae isolated in Japan
- (2021) Yasuhide Kawamoto et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Pneumonia Patients and Healthy Subjects
- (2021) Nao Kawaguchi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales
- (2021) Patricia J. Simner et al. Microbial Drug Resistance
- Clinical and Microbiological Characterization of Carbapenem-Resistant Enterobacteriales: A Prospective Cohort Study
- (2021) Qiuxia Lin et al. Frontiers in Pharmacology
- In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA
- (2021) Christi L. McElheny et al. Microbiology Spectrum
- Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections
- (2021) Casey Doremus et al. Infectious Diseases and Therapy
- Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study
- (2021) Minggui Wang et al. LANCET INFECTIOUS DISEASES
- Evaluation of patient risk factors for infection with carbapenem-resistant Enterobacteriaceae
- (2020) Marko Predic et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
- (2020) David van Duin et al. LANCET INFECTIOUS DISEASES
- Stepwise evolution and convergent recombination underlie the global dissemination of carbapenemase-producing Escherichia coli
- (2020) Rafael Patiño-Navarrete et al. Genome Medicine
- Structural basis of reduced susceptibility to ceftazidime–avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion
- (2020) Akito Kawai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime
- (2020) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective
- (2020) Sergio Reyes et al. Expert Review of Anti-Infective Therapy
- Subsequent carbapenem-resistant Enterobacteriaceae (CRE)–associated infections among hospitalized patients with CRE colonization: Impact of antibiotic use and other factors
- (2020) Thana Khawcharoenporn et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
- (2020) Ivan Titov et al. CLINICAL INFECTIOUS DISEASES
- Risk factors and outcomes of patients colonized with carbapenemase-producing and non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae
- (2020) Amal Kassem et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- The clinical and molecular epidemiology of non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae (non-CP-CRE): a case-case-control matched analysis
- (2020) Ruth Bouganim et al. Open Forum Infectious Diseases
- In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria
- (2020) Shazad Mushtaq et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model
- (2020) Shuhei Matsumoto et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review
- (2020) Zaira R. Palacios-Baena et al. CLINICAL MICROBIOLOGY AND INFECTION
- Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms
- (2020) Abigail K. Kois et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Incidence and risk factors of carbapenem-resistant Enterobacteriaceae infection in intensive care units: a matched case–control study
- (2020) Fahad A S Aleidan et al. Expert Review of Anti-Infective Therapy
- Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations
- (2020) Krisztina M. Papp-Wallace et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
- (2020) Naoki Kohira et al. Journal of Global Antimicrobial Resistance
- Compassionate Use of Cefiderocol to Treat a Case of Prosthetic Joint Infection Due to Extensively Drug-Resistant Enterobacter hormaechei
- (2020) Soline Siméon et al. Microorganisms
- Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
- (2020) Nao Kawaguchi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Impact of the Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae in Japan: A Matched Case-Case-Control Study
- (2020) Sho Saito et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem-resistant Enterobacterales bacteriuria and subsequent bacteremia: A population-based study
- (2020) Jessica R. Howard-Anderson et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Cefiderocol in the treatment of systemic carbapenemase-producing multidrug-resistant Klebsiella pneumoniae infection
- (2020) Temi Lampejo et al. Journal of Global Antimicrobial Resistance
- Once-Daily Plazomicin for Complicated Urinary Tract Infections
- (2019) Florian M.E. Wagenlehner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
- (2019) James A. McKinnell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration
- (2019) Shiro Miyazaki et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Aztreonam plus clavulanate, tazobactam or avibactam for the treatment of metallo-β-lactamase-producing-Gram negative related infections
- (2019) Cécile Emeraud et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models
- (2019) Rio Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report
- (2019) Enrico Maria Trecarichi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Co-Infections of Two Strains of NDM-1 and OXA-232 Co-producing Klebsiella pneumoniae in a Kidney Transplant Patient
- (2019) Deisy A. Contreras et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects
- (2019) Carlos Sanabria et al. CLINICAL THERAPEUTICS
- Screening for carriage of carbapenem-resistant Enterobacteriaceae in settings of high endemicity: a position paper from an Italian working group on CRE infections
- (2019) Simone Ambretti et al. Antimicrobial Resistance and Infection Control
- Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals During 2016-2018
- (2019) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
- (2019) Patrice Nordmann et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
- (2019) Yohei Doi CLINICAL INFECTIOUS DISEASES
- Predicting Carbapenem-Resistant Enterobacteriaceae Carriage at the Time of Admission Using a State-Wide Hospital Discharge Database
- (2019) Michael Y Lin et al. Open Forum Infectious Diseases
- 679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)
- (2019) Christopher Longshaw et al. Open Forum Infectious Diseases
- Long Term Compassionate Use of Cefiderocol to Treat Chronic Osteomyelitis Caused by XDR-Pseudomonas aeruginosa and ESBL-producing Klebsiella pneumoniae in a Pediatric Patient
- (2019) Zain I. Alamarat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013–17
- (2019) Krystyna M Kazmierczak et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
- (2018) Yutaka Saisho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection
- (2018) Keith S. Kaye et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa
- (2018) Islam M. Ghazi et al. PHARMACOLOGY
- Impact of amikacin pharmacokinetic/pharmacodynamic index on treatment response in critically ill patients
- (2018) Jesus Ruiz et al. Journal of Global Antimicrobial Resistance
- Efficacy of Humanized Cefiderocol Exposures Over 72 hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
- (2018) Sean M Stainton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
- (2018) James A. Karlowsky et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
- (2017) Matthew Sims et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Beta-lactamase database (BLDB) – structure and function
- (2017) Thierry Naas et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function
- (2016) Takayuki Katsube et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-ResistantEnterobacteriaceaeBacteremia
- (2016) Pranita D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment
- (2016) Takayuki Katsube et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae
- (2016) Ritu Banerjee et al. Virulence
- Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
- (2015) Eric Wenzler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens
- (2015) David P. Nicolau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
- (2012) M. Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- OXA-48-like carbapenemases: the phantom menace
- (2012) L. Poirel et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy
- (2011) J. Findlay et al. CLINICAL MICROBIOLOGY AND INFECTION
- Updated Functional Classification of -Lactamases
- (2009) K. Bush et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- AmpC -Lactamases
- (2009) G. A. Jacoby CLINICAL MICROBIOLOGY REVIEWS
- Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies
- (2008) Gopi Patel et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started